AMAL Therapeutics and ViraTherapeutics, in partnership with their common parent company, Boehringer Ingelheim, are very proud to announce that they have advanced their first-in-class heterologous prime-boost vaccine to Phase 1 studies  in patients with colorectal cancer in combination with Ezabenlimab (BI 754091). This advancement  is a result of several years of close and strong collaboration between the teams, which have recently also published their joint research in Nature Communications and Cancers.